Comparison of ocular surface side effects of topical travoprost and bimatoprost

Ophthalmologica

Volumn 222, Issue 3, 2008, Pages 161-167

  Alagöz, Gürsoy ^a   Bayer, Atilla ^b   Boran, Çetin ^a   Serin, Didem ^a   Kükner, Aysel ^a   Elçioǧlu, Mustafa ^a  

^a ABANT IZZET BAYSAL UNIVERSITY   (Turkey)

^b GULHANE SCHOOL OF MEDICINE   (Turkey)

Author keywords

Bimatoprost; Glaucoma; Tear film; Travoprost

Indexed keywords

BIMATOPROST; TRAVOPROST;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONJUNCTIVAL HYPEREMIA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRY EYE; EYE DISCOMFORT; EYE PAIN; FEMALE; HUMAN; IMPRESSION CYTOLOGY; INTRAOCULAR FOREIGN BODY; MAJOR CLINICAL STUDY; MALE; OCULAR PRURITUS; OPEN ANGLE GLAUCOMA; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SCHIRMER TEST; SINGLE BLIND PROCEDURE; TEAR FILM;

ADMINISTRATION, TOPICAL; ADULT; AGED; AGED, 80 AND OVER; AMIDES; ANTIHYPERTENSIVE AGENTS; CLOPROSTENOL; CONJUNCTIVA; FEMALE; FOLLOW-UP STUDIES; GLAUCOMA, OPEN-ANGLE; HUMANS; HYPEREMIA; MALE; MIDDLE AGED; OPHTHALMIC SOLUTIONS; PROGNOSIS; RISK FACTORS; SINGLE-BLIND METHOD;

EID: 44349151702     PISSN: 00303755     EISSN: None     Source Type: Journal    
DOI: 10.1159/000126078     Document Type: Article

References (43)

1. The American Academy of Ophthalmology: Preferred practice patterns: primary open angle glaucoma. Guidelines, 2005, pp 11-17.
2. Turacli E, et al: The effects of long-term topical glaucoma medication on conjunctival impression cytology. Int Ophthalmol 1997;21:27-33.
3. Arici MK, et al: Adverse effects of topical antiglaucoma drugs on the ocular surface. Clin Exp Ophthalmol 2000;28:113-117.
4. Brandt JD, et al: Conjunctival impression cytology in patients with glaucoma using longterm topical medication. Am J Ophthalmol 1991;112:297-301.
5. Sherwood MB, et al: Long-term morphologic effects of antiglaucoma drugs on the conjunctiva and Tenon's capsule in glaucomatous patients. Ophthalmology 1989;96:327-335.
6. Nuzzi R, et al: Conjunctiva and subconjunctival tissue in primary open-angle glaucoma after long-term topical treatment: an immunohistochemical and ultrastructural study. Graefes Arch Clin Exp Ophthalmol 1995;233:154-162.
7. Broadway DC, et al: Adverse effects of topical antiglaucoma medication. I. The conjunctival cell profile. Arch Ophthalmol 1994;112:1437-1445.
8. Herreras JM, et al: Ocular surface alteration after long-term treatment with an antiglaucomatous drug. Ophthalmology 1992;99:1082-1088.
9. Costagliola C, et al: Ocular surface changes induced by topical application of latanoprost and timolol: a short-term study in glaucomatous patients with and without allergic conjunctivitis. Graefes Arch Clin Exp Ophthalmol 2001;239:809-814.
10. Hugues FC, Le Jeunne C: Systemic and local tolerability of ophthalmic drug formulations: an update. Drug Saf 1993;8:365-380.
11. Lavin MJ, et al: The influence of prior therapy on the success of trabeculectomy. Arch Ophthalmol 1990;108:1543-1548.
12. Richter CU, et al: The development of encapsulated filtering blebs. Ophthalmology 1988;95:1163-1168.
13. Broadway D, Grierson I, Hitchings R: Adverse effects of topical antiglaucomatous medications on the conjunctiva. Br J Ophthalmol 1993;77:590-596.
14. Broadway DC, et al: Adverse effects of topical antiglaucoma medication. II. The outcome of filtration surgery. Arch Ophthalmol 1994;112:1446-1454.
15. Alm A, Stjernschantz J: Effects on intraocular pressure and side effects of 0.005% latanoprost applied once daily, evening or morning: a comparison with timolol. Scandinavian Latanoprost Study Group. Ophthalmology 1995;102:1743-1752.
16. Burstein NL: Corneal cytotoxicity of topically applied drugs, vehicles and preservatives. Surv Ophthalmol 1980;25:15-30.
17. Ichijima H, et al: Confocal microscopic studies of living rabbit cornea treated with benzalkonium chloride. Cornea 1992;11:221-225.
18. Pfister RR, Burstein N: The effects of ophthalmic drugs, vehicles, and preservatives on corneal epithelium: a scanning electron microscope study. Invest Ophthalmol 1976;15:246-259.
19. Burstein NL: Preservative cytotoxic threshold for benzalkonium chloride and chlorhexidine digluconate in cat and rabbit corneas. Invest Ophthalmol Vis Sci 1980;19:308-313.
20. Tripathi BJ, Tripathi RC, Kolli SP: Cytotoxicity of ophthalmic preservatives on human corneal epithelium. Lens Eye Toxic Res 1992;9:361-375.
21. Fellman RL, et al: Comparison of travoprost 0.0015 and 0.004% with timolol 0.5% in patients with elevated intraocular pressure: a 6-month, masked, multicenter trial. Ophthalmology 2002;109:998-1008.
22. Stewart WC, et al: Conjunctival hyperemia in healthy subjects after short-term dosing with latanoprost, bimatoprost, and travoprost. Am J Ophthalmol 2003;135:314-320.
23. Eisenberg DL, Toris CB, Camras CB: Bimatoprost and travoprost: a review of recent studies of two new glaucoma drugs. Surv Ophthalmol 2002;47(suppl 1):S105-S115.
24. Fechtner RD, et al: Anterior uveitis associated with latanoprost. Am J Ophthalmol 1998;126:37-41.
25. Callanan D, Fellman RL, Savage JA: Latanoprost-associated cystoid macular edema. Am J Ophthalmol 1998;126:134-135.
26. Moroi SE, et al: Cystoid macular edema associated with latanoprost therapy in a case series of patients with glaucoma and ocular hypertension. Ophthalmology 1999;106:1024-1029.
27. Parrish RK, Palmberg P, Sheu WP: A comparison of latanoprost, bimatoprost, and travoprost in patients with elevated intraocular pressure: a 12-week, randomized, masked-evaluator multicenter study. Am J Ophthalmol 2003;135:688-703.
28. Nelson JD, Havener VR, Cameron JD: Cellulose acetate impressions of the ocular surface: dry eye states. Arch Ophthalmol 1983;101:1869-1872.
29. DuBiner H, et al: Efficacy and safety of bimatoprost in patients with elevated intraocular pressure: a 30-day comparison with latanoprost. Surv Ophthalmol 2001;45(suppl 4):S353-S360.
30. Brandt JD, et al: Comparison of once- or twice-daily bimatoprost with twice-daily timolol in patients with elevated IOP: a 3-month clinical trial. Ophthalmology 2001;108:1023-1031, discussion 1032.
31. Sherwood M, Brandt J: Six-month comparison of bimatoprost once-daily and twicedaily with timolol twice-daily in patients with elevated intraocular pressure. Surv Ophthalmol 2001;45(suppl 4):S361-S368.
32. Abelson MB, et al: Multicenter, open-label evaluation of hyperemia associated with use of bimatoprost in adults with open-angle glaucoma or ocular hypertension. Adv Ther 2003;20:1-13.
33. Leal BC, et al: Conjunctival hyperemia associated with bimatoprost use: a histopathologic study. Am J Ophthalmol 2004;138:310-313.
34. Goldberg I, et al: Comparison of topical travoprost eye drops given once daily and timolol 0.5% given twice daily in patients with open-angle glaucoma or ocular hypertension. J Glaucoma 2001;10:414-422.
35. Netland PA, et al: Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension. Am J Ophthalmol 2001;132:472-484.
36. Young TL, et al: Effects of topical glaucoma drugs on fistulized rabbit conjunctiva. Ophthalmology 1990;97:1423-1427.
37. Cvenkel B, Ihan A: Ocular surface changes induced by topical antiglaucoma monotherapy. Ophthalmologica 2002;216:175-179.
38. Baudouin C, et al: Ocular surface inflammatory changes induced by topical antiglaucoma drugs: human and animal studies. Ophthalmology 1999;106:556-563.
39. Baudouin C, et al: Expression of inflammatory membrane markers by conjunctival cells in chronically treated patients with glaucoma. Ophthalmology 1994;101:454-460.
40. Schwab IR, et al: Foreshortening of the inferior conjunctival fornix associated with chronic glaucoma medications. Ophthalmology 1992;99:197-202.
41. Becquet F, et al: Histopathological effects of topical ophthalmic preservatives on rat corneoconjunctival surface. Curr Eye Res 1998;17:419-425.
42. Burstein NL: The effects of topical drugs and preservatives on the tears and corneal epithelium in dry eye. Trans Ophthalmol Soc UK 1985;104:402-409.
43. Takahashi N: A new method evaluating quantitative time-dependent cytotoxicity of ophthalmic solutions in cell culture: beta-adrenergic blocking agents. Graefes Arch Clin Exp Ophthalmol 1983;220:264-267.